Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 552 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allografts Clear all
Not listed Phase 2 Interventional

Efficacy of CTM for Tennis ELbow

NCT06171555
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis \(Tennis Elbow\), Lateral Elbow Tendinopathy
Interventions
CTM, Celestone
Device · Drug
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 6, 2026, 2:17 AM EDT
Withdrawn Phase 4 Interventional

An Amniotic Membrane Injection Comparing Two Doses (1 mL and 2mL Injection) in the Treatment of Osteoarthritis of the Knee

NCT04201743
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Acellular amniotic membrane derived allograft injection (NuDYN)
Drug
Lead sponsor
Illinois Center for Orthopaedic Research and Education
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 2:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

NCT03326076
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
Diagnostic Test · Other
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 6, 2026, 2:17 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 6, 2026, 2:17 AM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Buccal Mucosa Healing Trial With Tissue Matrix Placement

NCT02768467
View directory record Official record
Conditions
Tissue Grafts
Interventions
Tissue Matrix Graft Placement, No Stitches
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 6, 2026, 2:17 AM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

NCT01157949
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures

NCT00837473
View directory record Official record
Conditions
Iliac Crest Harvesting Procedure-Bone Void Filler
Interventions
Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Device
Lead sponsor
Osteotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting Phase 4 Interventional

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

NCT07657182
View directory record Official record
Conditions
Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury, Upper Extremity Nerve Injury
Interventions
Avance Nerve Graft, Sural nerve autograft
Biological · Procedure
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy

NCT00344890
View directory record Official record
Conditions
Cervical Radiculopathy, Myelopathy
Interventions
Anterior Cervical Discectomy and Fusion
Procedure
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional

Comparison of Two Types of Bone Grafts in Patients Who Need One of Their Front Teeth Removed and Replaced With an Implant

NCT06722482
View directory record Official record
Conditions
Ridge Preservation, Allografts, Extraction, Tooth, Xenograft
Interventions
FDBA, CEBX
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Not yet recruiting Not applicable Interventional

Allograft vs. Autograft Nonunion

NCT07310082
View directory record Official record
Conditions
Nonunion Fracture
Interventions
Autograft, Allograft
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 6, 2026, 2:17 AM EDT
Not listed Phase 1Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

NCT00498160
View directory record Official record
Conditions
Renal Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Vascularized Composite Allotransplantation of the Hand and Upper Extremity (Hand Transplant)

NCT02165865
View directory record Official record
Conditions
Traumatic Amputation of Arm, Traumatic Amputation of Hand
Interventions
upper extremity/ hand transplantation
Procedure
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 69 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 6, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

NCT00260234
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Face Transplantation for Treatment of Severe Facial Deformity

NCT01281267
View directory record Official record
Conditions
Severe Facial Deformity
Interventions
Facial Allograft Transplantation
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 6, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ridge Preservation Comparing 2 Membranes

NCT01905280
View directory record Official record
Conditions
Alveolar Ridge Deficiency
Interventions
Non-resorbable membrane, Acellular dermal matrix
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 6, 2026, 2:17 AM EDT
Terminated No phase listed Observational

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

NCT02115503
View directory record Official record
Conditions
Renal Transplant Recipients With Anti-HLA Antibodies
Interventions
Not listed
Lead sponsor
Databean
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 6, 2026, 2:17 AM EDT